Ciliary sulcus implants and methods of using same

JP2023549680A5Active Publication Date: 2024-11-06SPYGLASS OPHTHALMICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526063
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-02
Filing Date
2021-10-28
Publication Date
2024-11-06
Estimated Expiration
2041-10-28

AI Technical Summary

Technical Problem

Conventional intraocular implants face limitations in manufacturability and safety, often causing tissue damage during implantation.

Method used

Development of an intraocular implant with a ring or partial ring structure featuring a rigid outer component and deformable haptics, designed for implantation in the ciliary sulcus or capsular bag, utilizing materials with different chemical compositions to minimize tissue damage and enhance manufacturability.

Benefits of technology

The implant maintains its shape while the haptics deform under ocular conditions, reducing tissue trauma and improving manufacturability, allowing for safer and more effective implantation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides an ocular implant, such as a ciliary sulcus implant, that can include one or more drug delivery devices. Further provided herein is a method of using the drug delivery ocular device described herein for implantation into a subject's eye, for example, the ciliary sulcus or capsular bag of the eye. The implant includes a ring or partial ring comprising a first material and configured for implantation into the subject's eye, the ring or partial ring being characterized by an outer circumferential surface, an inner wall, and a central opening 17, and closed-loop haptics comprising a second material and attached to the ring or partial ring at first and second haptic ends. The first and second materials have different chemical compositions, and the ring or partial ring is more rigid than the closed-loop haptics.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to ciliary sulcus implants and methods of using ciliary sulcus implants. [Background technology]

[0002] Conventional intraocular implants can be limited in their manufacturability and their ability to provide a therapeutic effect without damaging ocular tissue when implanted. Thus, there is an unmet need for intraocular implants that offer improved safety and reduced tissue damage during use, as well as improved manufacturability. Summary of the Invention [Problem to be solved by the invention]

[0003] Provided herein are intraocular implants that can be implanted in a subject's eye. In some cases, provided herein are intraocular implants for implantation in the ciliary sulcus or capsular bag of a subject's eye. [Means for solving the problem]

[0004] In various embodiments, the ocular implant includes a ring or partial ring 15 including a first material and configured for implantation in a subject's eye, the ring or partial ring 15 characterized by an outer circumferential surface, an inner wall, and a central opening 17, and closed-loop haptics 16, 16C, 16L, 43, 46 including a second material and attached to the ring or partial ring at first haptic ends 16d, 41, 45 and second haptic ends 16d, 42, 44. The first and second materials have different chemical compositions, and the ring or partial ring is stiffer than the closed-loop haptics.

[0005] In some embodiments, under conditions present in the eye after implantation, the ring or partial ring retains its shape and the closed-loop haptics deform. In other embodiments, at an applied force of 100 mN, the ring or partial ring retains its shape and the closed-loop haptics deform. In a further embodiment, at an applied force of 10 mN, the ring or partial ring retains its shape and the closed-loop haptics deform.

[0006] In certain aspects, the ocular implant comprises a plurality of closed-loop haptics. In some embodiments, the first haptic end is flexibly connected to the ring at the first haptic end such that the closed-loop haptics are deformable by forces applied by the tissue in which the implant is implanted.

[0007] In other embodiments, portions of the closed loop haptics pass through holes 18, 49, 50, 84 in the ring and into a central opening to form a gripping feature 21, 85. In some embodiments, the second haptic end is flexibly connected to the ring at the second haptic end such that the closed-loop haptics are deformable by forces applied by the tissue in which the implant is implanted.

[0008] In some embodiments, the closed-loop haptics are configured such that the first haptic end, the second haptic end, or a combination thereof, is disposed within a recess in ring 15 .

[0009] In other aspects, the first haptic end is attached to the ring by mechanically fastening the first haptic end to the ring, overmolding the first haptic end with the ring, fusing the first haptic end to the ring, attaching the first haptic end to the ring with a heat shrink attachment, attaching the first haptic end to the ring with an adhesive, or a combination thereof.

[0010] In certain embodiments, the second haptic end is attached to the ring by mechanically fastening the second haptic end to the ring, overmolding the second haptic end with the ring, fusing the second haptic end to the ring, attaching the second haptic end to the ring with a heat shrink attachment, attaching the second haptic end to the ring with an adhesive, or a combination thereof.

[0011] In some embodiments, the first material is a biocompatible material and the second material is a biocompatible material. In other embodiments, the first material is a first polymer and the second material is a second polymer. In certain embodiments, the first material is selected from the group consisting of silicone, acrylic, hydroxyethyl methacrylate (HEMA), polyethyl methacrylate (PEMA), and polyethyl acrylate (PEA), or any combination thereof.

[0012] In some embodiments, the second material is an elastomer, hi other embodiments, the second material is selected from the group consisting of polymethylmethacrylate (PMMA), polyvinylidene fluoride (PVDF), polypropylene (PP), and polyethersulfone (PES), or any combination thereof.

[0013] In various embodiments, the ocular implant includes a ring or partial ring 15 configured for implantation in a patient's eye, characterized by an outer circumferential surface, an inner wall, and a central opening 17, and haptics 16, 16L, 43, 46 connected to the ring at first haptic ends 16d, 41, 43 and second haptic ends 16d, 42, 44. The haptics are flexibly connected to the ring at the first haptic ends such that the haptics are deformable by forces applied by tissue into which the implant is implanted.

[0014] In some embodiments, the haptics are flexibly connected to the ring at the second haptic end such that the haptics are deformable by forces applied by the tissue in which the implant is implanted.

[0015] In other embodiments, the haptics are configured such that the first haptic end, the second haptic end, or a combination thereof, is positioned within recesses 37, 52, 53 of ring 15.

[0016] In certain embodiments, the ring includes holes 18, 36, 47, 48, 49, 50, 52, 53 that lead from the outer peripheral openings 19, 51, 56, 57 toward the inner wall. In some embodiments, the second haptic end 16d, 42, 44 is slidably disposed within the holes 18, 36, 48, 50, 52.

[0017] In various aspects, the ocular implant is configured for implantation in the posterior chamber and ciliary sulcus of a subject's eye. In some embodiments, the second haptic end is flexibly connected to the ring at the second haptic end such that the haptics are deformable by forces applied by the tissue in which the implant is implanted.

[0018] In certain embodiments, the second haptic end is attached to the ring by mechanically fastening the second haptic end to the ring, overmolding the second haptic end with the ring, fusing the second haptic end to the ring, attaching the second haptic end to the ring with a heat shrink attachment, attaching the second haptic end to the ring with an adhesive, or a combination thereof.

[0019] In various aspects, the present disclosure provides an ocular implant configured for implantation in a subject's eye. The ocular implant includes a ring 15 configured for implantation in a subject's eye, the ring 15 being characterized by an outer circumferential surface, an inner wall, and a central opening 17, and haptics 16, 16L, 43, 46 connected to the ring at first haptic ends 16d, 41, 45 and second haptic ends 16d, 42, 44. The ring includes holes 18, 49, 50 leading from openings 19, 51 in the outer circumferential surface toward the inner wall. The second haptic ends 16d, 42, 44 are positioned within and slidably disposed within the holes 18, 48, 50, 52, such that the haptics are deformable by forces applied by tissue into which the implant is implanted, which may act to press the second haptic ends into the holes 18, 48, 50, 52.

[0020] In various aspects, the present disclosure provides an ocular implant configured for implantation in the posterior chamber and ciliary sulcus of a subject's eye. The ocular implant includes a ring 15 configured for implantation in the posterior chamber of the subject's eye, the ring 15 being characterized by an outer circumferential surface, an inner wall, and a central opening 17; and haptics 16, 16L, 43, 46 connected to the ring at first haptic ends 16d, 41, 45 and second haptic ends 16d, 42, 44, the ring having holes 18, 49, 50 leading from the outer circumferential opening 19, 51 toward the inner wall, the second haptic ends 16d, 42, 44 positioned within and slidably disposed within the holes 18, 48, 50, 52, such that the haptics are deformable by a force applied by tissue into which the implant is implanted and acting to urge the second haptic ends into the holes 18, 48, 50, 52.

[0021] In some embodiments, second haptic end 16d, 42, 44 comprises a haptic distal tip 16T having a larger cross-section than the remainder of second haptic end 16d, 42, 44.

[0022] In another aspect, the second haptic end 16d, 42, 44 has a haptic distal tip 16T having a larger cross-section than the remainder of the second haptic end 16d, 42, 44, and the through-hole 18, 36, 48, 50 has an inner cavity with a smaller cross-section than the haptic distal tip 16T, thereby inhibiting or preventing the second haptic end from slipping out of the through-hole.

[0023] In some embodiments, the ocular implant further comprises a gripping feature 21 disposed on the second haptic end 16d, 42, 44, said gripping feature configured for engagement of a gripping instrument.

[0024] In another aspect, the holes 18,50 leading from the openings 19,51 in the outer peripheral surface toward the inner wall are through holes communicating with the openings 20,56 in the inner wall of the ring, and the second haptic end 16d,42,44 has a haptic distal tip 16T having a larger cross section than the remainder of the second haptic end 16d,42,44, and the haptic distal tip 16T is positioned in the central opening 17.

[0025] In further embodiments, first haptic end 16d, 41, 45 includes a haptic distal tip 16T having a larger cross-section than the remainder of first haptic end 16d, 41, 45.

[0026] In some embodiments, the first haptic end 16d, 41, 45 has a haptic distal tip 16T having a larger cross-section than the remainder of the first haptic end, and the through-hole 18, 47, 49 has an inner cavity with a smaller cross-section than the haptic distal tip 16T, thereby inhibiting or preventing the first haptic end from slipping out of the through-hole.

[0027] In other embodiments, the ocular implant further comprises a gripping feature 21 disposed on the first haptic end 16d, 41, 45, said gripping feature configured for engagement of a gripping instrument.

[0028] In a particular embodiment, the hole 18,49 leading from the opening 19,51 in the outer peripheral surface toward the inner wall is a through hole communicating with the opening 20,57 in the inner wall of the ring, and the first haptic end 16d,41,45 has a haptic distal tip 16T having a larger cross section than the remainder of the first haptic end, said haptic distal tip 16T being positioned in the central opening 17.

[0029] In some embodiments, the holes 18, 52, 53, 49, 50 are radially oriented within the ring. In other embodiments, the holes 18, 52, 53, 49, 50 are chordally oriented within the ring. In further embodiments, the holes 18, 49, 50 are through holes that communicate with an opening in the inner wall of the ring or in the front face of the ring. In additional elements, the holes 18, 52, 53 are blind holes that are terminated by the ring.

[0030] In some embodiments, the first haptic end is flexibly connected to the ring at the second haptic end such that the haptics are deformable by forces applied by the tissue in which the implant is implanted.

[0031] In certain embodiments, the first haptic end is attached to the ring by mechanically fastening the first haptic end to the ring, overmolding the first haptic end with the ring, fusing the first haptic end to the ring, attaching the first haptic end to the ring with a heat shrink attachment, attaching the first haptic end to the ring with an adhesive, or a combination thereof.

[0032] In other embodiments, the ring comprises a first biocompatible material and the haptics comprise a second biocompatible material. In some embodiments, the first biocompatible material and the second biocompatible material have different chemical compositions, and the ring or partial ring is stiffer than the haptics.

[0033] In some aspects, under conditions present in the eye after implantation, the ring or partial ring retains its shape and the closed-loop haptics deform. In some embodiments, at an applied force of 100 mN, the ring or partial ring retains its shape and the closed-loop haptics deform. In other embodiments, at an applied force of 10 mN, the ring or partial ring retains its shape and the closed-loop haptics deform.

[0034] In certain embodiments, the first biocompatible material is a first polymer and the second biocompatible material is a second polymer, hi some aspects, the first biocompatible material is selected from the group consisting of silicone, acrylic, hydroxyethyl methacrylate (HEMA), polyethyl methacrylate (PEMA), and polyethyl acrylate (PEA), or any combination thereof.

[0035] In some embodiments, the second biocompatible material is an elastomer. In certain embodiments, the second biocompatible material is selected from the group consisting of polymethylmethacrylate (PMMA), polyvinylidene fluoride (PVDF), polypropylene (PP), and polyethersulfone (PES), or any combination thereof.

[0036] In some embodiments, the ocular implant further comprises a drug delivery structure. In certain embodiments, the ocular implant further comprises a lens 34 disposed within the central opening 17 .

[0037] In various embodiments, the ocular implant comprises first and second arcuate drug delivery structures 70 configured for implantation in a subject's eye, the first and second arcuate drug delivery structures 70 having an outer contour 70C configured for placement in the sulcus and containing a therapeutic agent configured to treat an ocular condition or disease of the subject; and first and second biasing members 71 connecting the first and second arcuate drug delivery structures, the first and second biasing members 71 being configured to be elastically expandable and compressible to bias the first and second drug delivery structures away from each other to configure the sulcus implant to a larger diameter configuration and to enable compression of the sulcus implant to a smaller diameter configuration.

[0038] In various embodiments, the ocular implant comprises an arcuate drug delivery structure 70 configured for implantation in the ciliary sulcus of a subject's eye, the arcuate drug delivery structure 70 having an outer contour 70C configured for placement in the ciliary sulcus and containing a therapeutic agent configured to treat an ocular condition or disease of the subject; and a biasing member 71 connected to the arcuate drug delivery structure, the biasing member 71 configured for implantation in the ciliary sulcus of a subject's eye and configured to be elastically expandable and compressible to bias the arcuate drug delivery structure away from one end of the biasing member to configure the ciliary sulcus implant to a larger diameter configuration and to allow compression of the ciliary sulcus implant to a smaller diameter configuration.

[0039] In various embodiments, the ocular implant comprises a drug delivery structure having an elastically expandable and compressible wire frame 80 and panels 81, 82 connected by struts 83, the panels and struts defining an opening, and a portion of the compressible wire frame is positioned within the opening.

[0040] In some embodiments, the ocular implant is configured to resiliently expand until the outer contour contacts the ciliary sulcus of the eye. In some embodiments, the arcuate drug delivery structure 70 contains a therapeutic agent.

[0041] In certain embodiments, drug delivery structures 27, 81, 82 contain a therapeutic agent. In certain aspects, the drug delivery structures are selected from the group consisting of a therapeutic agent, a therapeutic agent disposed in a matrix, an erodible therapeutic agent, and a therapeutic agent in a matrix forming a drug-eluting structure, or combinations thereof. In some embodiments, drug delivery structure 27 is disposed on posterior surface 15P of ring 15. In certain aspects, the therapeutic agent is disposed in a matrix forming a drug-eluting structure. In some aspects, the drug delivery structure is disposed within ring or partial ring 15 or arcuate drug delivery structure 70. In some embodiments, the drug delivery structure or arcuate drug delivery structure 70 comprises a polymer matrix containing a therapeutic agent. In certain embodiments, the polymer matrix is ​​bioerodible. In further embodiments, the therapeutic agent comprises one or more of a prostaglandin analog, an alpha agonist, a Rho-kinase (ROCK) inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic and / or cholinergic receptor activator, a steroid, an aptamer, a complement factor, an antioxidant, an anti-inflammatory agent, an antibody, an antiproliferative agent, an antimitotic agent, or an anti-inflammatory agent. In certain embodiments, the prostaglandin analog comprises bimatoprost.

[0042] In various embodiments, the present disclosure provides methods of treating an ocular condition or disease in a subject in need thereof, the method comprising providing an ocular implant as described herein and implanting the ocular implant into the eye of the subject, thereby treating the ocular condition or disease in the subject.

[0043] In some aspects, the method includes compressing the ocular implant into an injector, inserting a portion of the injector into the subject's eye, and releasing the ocular implant into the subject's eye. In other aspects, the method includes implanting the ocular implant into the posterior chamber and ciliary sulcus of the subject's eye. In other aspects, the method includes implanting the ocular implant into the lens capsule of the subject's eye.

[0044] In other aspects, the method further comprises delivering a therapeutic agent from the ocular implant to the subject's ocular tissue. In certain embodiments, the therapeutic agent is delivered by eluting the therapeutic agent from a matrix containing the therapeutic agent. In a further aspect, the therapeutic agent is a prostaglandin analog. In an additional embodiment, the therapeutic agent is bimatoprost.

[0045] In some embodiments, the ophthalmic condition or disease is selected from the group consisting of age-related macular degeneration, amblyopia (lazy eye), cataracts, color blindness, diabetic retinopathy, dry eye, floaters, glaucoma, conjunctivitis, refractive errors, and retinal detachment, or a combination thereof. In particular embodiments, the ophthalmic condition or disease is glaucoma.

[0046] In certain embodiments, the subject has previously received an intraocular device implanted in the capsular bag of the subject's eye. In other embodiments, the method further includes using the gripping features 21,85 to manipulate the device within the eye.

[0047] In some embodiments, the present disclosure provides an ocular implant comprising a ring configured for implantation in a patient's eye and a passageway 18 communicating from an opening 19 adjacent the periphery of the ring to an opening 19 adjacent the inner wall of the ring.

[0048] In other aspects, the present disclosure provides an ocular implant including a ring configured for implantation in the posterior chamber of a patient's eye and a passageway 18 communicating from an opening 19 proximate the periphery of the ring to an opening 19 proximate the inner wall of the ring. In various aspects, provided herein are methods for treating an ocular condition in a subject. The method includes providing an ocular implant including a ring configured for implantation in the lens capsule of a subject's eye and a passageway 18 communicating from an opening 19 proximate the periphery of the ring to an opening 19 proximate the inner wall of the ring, and implanting the ring in the lens capsule of the eye such that the passageway allows aqueous humor to flow from the inner wall of the ring to the opening 19 proximate the periphery of the ring, allowing therapeutic agent to flow from the central opening to the equator of the lens capsule. In some cases, such methods can further include a drug delivery structure secured to the ring, where the drug delivery structure contains bimatoprost, and the method involves implanting the ocular implant to treat glaucoma. In some cases, such methods may further include a drug delivery structure secured to the ring, the drug delivery structure containing a therapeutic agent that may function to inhibit the proliferation and activity of lens endothelial cells in the equator and posterior capsule of the lens, and the method involves implanting an ocular implant to inhibit the proliferation and activity of lens endothelial cells in the equator and posterior capsule of the lens.

[0049] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0050] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: [Brief explanation of the drawings]

[0051] [Figure 1]1 is a diagram showing an environment in which an intraocular drug delivery system is used. [Figure 2] 1 is a diagram showing an environment in which an intraocular drug delivery system is used. [Figure 3] FIG. 3 illustrates a drug delivery platform configured for use in the ciliary sulcus of the eye as shown in FIG. 2. [Figure 4] Side view of Figure 3. [Figure 5] FIG. 4 is a front perspective view of the drug delivery platform of FIGS. 2 and 3. [Figure 6] 10 shows a drug delivery system configured to allow posterior access to the haptic tips. [Figure 7] 10 shows a drug delivery system configured to allow posterior access to the haptic tips. [Figure 8] FIG. 10 illustrates a ciliary sulcus IOL configured with captured haptic tip features. [Figure 9] FIG. 9 is a side view showing the front opening of the through-hole of the device of FIGS. 6 to 8. [Figure 10] 8A to 8C are diagrams showing modifications that can be applied to the devices of FIGS. 2 to 7. [Figure 11] 1 illustrates a drug delivery platform in combination with an implant having one or more aqueous humor flow holes and configured for use in the ciliary sulcus of the eye. [Figure 12] FIG. 12 is a front perspective view of the drug delivery platform of FIG. [Figure 13] FIG. 12 is a front perspective view of the drug delivery platform of FIG. [Figure 14] Illustrates a ciliary sulcus lens modified by an aqueous humor opening. [Figure 15] 1 illustrates a drug delivery ciliary sulcus implant configured for use in the ciliary sulcus of the eye, according to an embodiment of the present disclosure. [Figure 16] 16 illustrates the drug delivery ciliary sulcus implant shown in FIG. 15 in a compressed configuration, according to an embodiment of the present disclosure. [Figure 17] 1 illustrates a drug delivery platform having a biasing member integrally formed with the drug delivery structure according to an embodiment of the present disclosure. [Figure 18] 18 illustrates the compressed configuration of FIG. 17, a drug delivery platform having a biasing member integrally formed with the drug delivery structure, according to an embodiment of the present disclosure. [Figure 19] FIG. 1 illustrates a drug delivery platform having a single arcuate drug delivery structure according to an embodiment of the present disclosure. [Figure 20] 1 illustrates a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible wire frame according to an embodiment of the present disclosure. [Figure 21] 1 illustrates a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible ring according to an embodiment of the present disclosure. [Figure 22] 22 illustrates a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible ring according to an embodiment of the present disclosure, showing the device of FIG. 21 compressed. [Figure 23] 1 illustrates a drug delivery platform with closed-loop haptics and A-shaped haptics according to an embodiment of the present disclosure. [Figure 24] 1 illustrates a drug delivery platform with closed-loop haptics and retention features according to an embodiment of the present disclosure. [Figure 25] 1 illustrates a drug delivery platform with closed-loop haptics and A-shaped haptics according to an embodiment of the present disclosure. [Figure 26] 10A-10C illustrate a drug delivery platform comprising multiple closed-loop haptics attached to a compressible partial ring, according to an embodiment of the present disclosure. [Figure 27] 1 illustrates a drug delivery platform having a biasing member integrally formed with the drug delivery structure according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE INVENTION

[0052] The present disclosure provides intraocular devices for implantation in a subject's eye. The devices provided herein can be implanted in various regions of a subject's eye. In various embodiments, provided herein are intraocular devices for implantation in the ciliary sulcus of a subject's eye, as described herein.

[0053] As used herein, unless otherwise defined, the terms "ocular device," "ocular implant," "intraocular device," etc. may be used interchangeably and generally refer to a device that can be implanted in one or more specific locations in a subject's (e.g., human) eye.

[0054] 1 and 2 illustrate the placement and use of an intraocular drug delivery system or other ocular implant in a subject's eye. Eye 1 comprises a lens 2 and lens capsule 3, an anterior chamber 4 containing a cornea 5 and iris 6 and aqueous humor filling the space between the cornea and iris, and a posterior chamber 7 between the iris and lens capsule. The posterior chamber / vitreous body 8 is the large space between the lens and retina 9. The eye's natural lens 2 is characterized by an optical axis 10. The ciliary sulcus 11 is an annular space surrounding the posterior chamber, located between the posterior surface of the iris 6 and the anterior surface of the ciliary body 12. (In the following description of intraocular implants, the terms posterior and anterior are used with reference to the anatomy of the eye, in which the cornea is anterior and the retina is posterior.) Aqueous humor nourishes the lens and cornea and maintains pressure within the eye. Aqueous humor flows inward in the ciliary sulcus between the lens capsule / lens and the iris, then forward through the opening in the iris into the anterior chamber (the open space between the iris and lens and the cornea), and then radially outward between the iris and cornea, where it drains through structures within the sclera, specifically Schlemm's canal and veins (not shown) within the sclera.

[0055] FIG. 2 illustrates the placement of a ciliary sulcus implant / drug delivery platform 13 in an eye. In many cases where a ciliary sulcus implant / drug delivery platform is implanted, the subject may already have an intraocular lens 14 placed in the capsular bag after removing the natural lens. In this example, the ciliary sulcus implant / drug delivery platform is provided in the form of a ring 15, which is implanted, alone or with another implant, into the posterior chamber 7 and ciliary sulcus 11. As shown in FIG. 2 , the ciliary sulcus implant / drug delivery platform 13 is positioned in the ciliary sulcus of the posterior chamber 7, posterior to the iris 6 and anterior to the ciliary body 12, or more generally, anterior to the anterior lens capsule. The ciliary sulcus implant / drug delivery platform 13 is held in place by haptics 16 affixed to the ciliary sulcus implant / drug delivery platform 13, which are configured to engage tissue in the ciliary sulcus and center the ciliary sulcus implant / drug delivery platform 13 relative to the optical axis 10 of the eye. The haptics accommodate various ciliary sulcus diameters and are elastically biased outward after implantation so that the haptics expand until they contact tissue on the margin of the ciliary sulcus. The ciliary sulcus can have the following dimensions: 11.55 ± 0.38 mm at 45 degrees, 11.99 ± 0.36 mm at 90 degrees, 11.54 ± 0.36 mm at 135 degrees, and 11.32 ± 0.40 mm at 180 degrees, where the vertical diameter can be larger than the horizontal diameter, with a mean difference between the vertical and horizontal diameters of approximately 0.67 ± 0.26 mm (range, 0.36-1.13 mm).

[0056] I. Intraocular implants Provided herein is an intraocular implant that can include one or more U-loop haptics as described herein. In some embodiments, such an intraocular implant is a ciliary sulcus implant (e.g., for implantation in the ciliary sulcus of a subject's eye) that includes one or more U-loop haptics. In an embodiment, FIG. 3 is a front view of the ciliary sulcus implant / drug delivery platform of FIG. 2. The drug delivery platform includes a ring 15, which can be flat like a washer, with planar anterior and posterior surfaces 15A and 15P (e.g., as shown in FIG. 4), drug delivery structures 27, and a central opening 17. In other embodiments, each of the anterior and posterior surfaces 15A and 15P may not be independently planar and may include rounded peaks instead of sharp radii at the ends. Ring 15 preferably (e.g., in this embodiment) includes radially oriented through-holes 18 that communicate between openings 19 in the outer periphery of the ring and openings 20 in the inner surface of the ring between the anterior and posterior surfaces of the ring, without communicating with either the anterior or posterior surface of the ring. In some embodiments, radially oriented through-holes 18 may be replaced by openings having only an anterior cover (no posterior surface). In this embodiment, the posterior surface forms a through-hole that rests against the anterior surface of the lens capsule and retains the distal tips of the haptics.

[0057] The base 16B ("first end") of the haptic is secured to the ring in any suitable manner, including mechanically securing the haptic to the ring, overmolding the haptic with the ring, fusing the haptic to the ring, attaching the haptic to the ring with a heat-shrink attachment, attaching the haptic to the ring with an adhesive, or any other suitable attachment such that it cannot move relative to the ring. Haptic 16 includes a loop portion 16L and has a "free end" or tip 16T ("second end" or "terminal end") remote from haptic base 16B. The loop portion extends radially from the junction of haptic base 16B with the ring and curves back toward the ring, where haptic tip 16T enters through-hole 18 and preferably passes through the through-hole so that the tip is exposed within central opening 17. U-loop haptics or horseshoe haptics differ from typical C-loop haptics and J-loop haptics in that the haptics arc from the base so that the loop portion extends along an arc sufficient to return to the ring and enter the through hole (and preferably extend through the through hole into the central opening), and differ from plate haptics or loop haptics in that the tip is not fixedly attached to the ring.

[0058] The tip may preferably be configured to facilitate engagement with a Sinskey hook, micro-grasping forceps, or other instrument. As shown, the tip is configured with a gripping feature 21 such as an eyelet, although other configurations may be used, such as a pinhole (sized to accept a Sinskey hook), optional serrations, flanges, barbs, wrench flats, or other flat surfaces that can be gripped by a micro-grasping forceps. If other suitable gripping instruments are available, or if manipulation as described below is not anticipated, the tip may terminate in a blunt end without a gripping feature.

[0059] The distal end 16d of the haptic, including the tip 16T and a short portion proximal to the tip, is configured to be loosely disposed within the radial through-hole 18, and the radial through-hole is correspondingly configured to loosely receive the distal end 16d of the haptic, including the tip 16T. The haptic distal end, particularly the portion disposed within the radial through-hole, has a front-to-rear dimension (arrow 22 in FIG. 4 ) such that the distal end 16d can slide within the through-hole, a dimension corresponding to the circumference of a ring (arrow 23 in FIG. 4 ) sized relative to the front-to-rear dimension of the radial through-hole (arrow 24 in FIG. 4 ), and a dimension corresponding to the circumferential width of the through-hole (arrow 25 in FIG. 3 ), and the distal end 16d can translate radially (or longitudinally) within the through-hole. The gripping features 21 can be larger in one or other dimension (arrows 26 in FIG. 4 ) than the corresponding dimension of the radial through-hole to prevent the distal tips from slipping out of the radial through-hole and becoming unsecured to the ring (the gripping features preferably act as mechanical stops that prevent the haptics from slipping radially outward through the through-hole). The illustrated eyelets, for example, have a diameter larger than the circumferential width of the through-hole, identified by arrow 25. This configuration reduces the radially inward forces applied to the haptic loops by the edges of the ciliary sulci. These forces act to push the tips 16T and distal ends 16d of the haptics into the through-holes and toward / into the central opening, avoiding the transfer of radially inward forces to the ring that could otherwise deform the ring. The result of the radially inward forces on the haptics is shown in phantom in FIG. 3 , with the distal ends 16d and gripping features 21 displaced radially inward. Additionally, because the distal tip is constrained within the through-hole, the tip cannot be pushed into the iris or ciliary body by forces applied by anatomical structures or manipulation during implantation or removal, as with C-loop or J-loop haptics, thereby minimizing or eliminating the risk of trauma from the tip.Additionally, as described below, the gripping features can be used to pull the haptics out of the ciliary sulcus and detach the haptics from the iris and ciliary body, without the need to insert an instrument into the ciliary sulcus and pass the instrument tip over these structures.

[0060] Thus, without the need to insert an instrument into the ciliary sulcus or posterior chamber, the haptics can be removed from the ciliary sulcus position without engaging the iris or surrounding tissue and elevated above the resting plane for easier removal, thus minimizing trauma to associated tissue. These haptic loops can also aid in device placement during initial implantation, allowing the haptics to be gathered (toward the geometric center of the overall device) and then released (allowing them to open into the ciliary sulcus) when the ring is properly positioned. The constrained nature of the haptics will also make folding the device for insertion into the eye easier and more reproducible. This is because the haptics are constrained in a known space and axis, making it easier to compress the device into the injector and then inject or place it into the eye.

[0061] FIG. 4 is a side view of the drug delivery platform of FIGS. 2 and 3, showing the height of the through-holes and the anterior-posterior dimensions of the haptics, which may closely match. Also shown is the outer periphery 15C. The haptic tips and gripping features may have an anterior-posterior dimension greater than the anterior-posterior dimension of the through-holes. In this side view, the drug delivery structure 27 is shown on the posterior surface 15P of the ring 15. The anterior surface 15A is substantially flat in this illustration, which is preferred to minimize irritation of the iris. The anterior surface may be smoothly curved but may lack protrusions such as the drug delivery devices and / or compartments shown in other figures. FIG. 5 is a front perspective view of the device of FIG. 4. The drug delivery structure may also be positioned in a recess in the anterior surface of the ring, configured with a flat or smoothly curved anterior surface, so that the anterior surface of the drug delivery structure fits within the recess without extending forward beyond the anterior surface of the ring. The angle α of the inclination or vault angle of the haptics relative to the plane of the ring, measured forward from the base of the haptics, is preferably between about 0° and about 20°, between about 0° and about 10°, or between 0° and about 5°.

[0062] The drug delivery structures may be positioned as shown in FIG. 3 , but may also be positioned around the ring, e.g., radially aligned or adjacent to the haptic base and haptic openings, or around the entire periphery of the posterior surface of the ring ( FIG. 10 ). The drug delivery structures can also function as structural elements to increase the stability / rigidity of the very thin silicone and may be positioned to enhance the ability of the silicone ring to hold open (i.e., minimize deformation from its unconstrained circular form and avoid or minimize “ovalization” after implantation). The bases of the haptics may also extend further into the body of the silicone to further enhance the stability of the ring. The bases of the haptics shown in FIG. 3 extend into the ring and may extend circumferentially inside the ring to stabilize it. When the haptics are constructed of a material that is more rigid than the ring, which may preferably be formed of silicone, extending inside the ring helps increase the rigidity of the assembled haptics and ring.

[0063] At the rear surface 15P, the drug delivery platform may comprise one or more drug delivery structures 27. The drug delivery structures may be fixed directly to the rear surface or the drug delivery structures may be disposed in compartments.

[0064] The drug delivery structure configured for placement on the ring may be provided as a drug depot or drug mass in the form of a block, slab, wafer, etc. containing a therapeutic agent or therapeutic agent disposed in a matrix, or may contain an erodible therapeutic agent or a therapeutic agent in a matrix that forms a drug-eluting structure.

[0065] FIG. 6 illustrates a drug delivery system configured to allow rearward access to the haptic tips. FIGS. 7 and 8 illustrate drug delivery systems configured to allow access to the haptic tips. If it is desired to block the central opening, for example, with a lens or other component, the haptic tips and through-holes can be configured according to FIGS. 6 and 7, which minimize the transfer of radial compressive forces applied to the haptics by surrounding eye tissues, eliminating the possibility of trauma to the iris by the haptic tips during implantation and removal, while retaining the functionality to grasp the haptic tips to release them from the ciliary sulcus. In FIG. 6, the through-holes communicate from the opening 19 in the anterior surface 15A of the ring to the rear opening 32P in the posterior surface 15A of the ring. The ring can include a drug delivery structure 27 disposed within the ring. The ring includes a hole 32 through which the haptic tips 16T (at the distal ends 16d of the haptics) can extend. The gripping features 21 may extend rearward and radially inward beyond the rear opening 32P, as shown in FIG. 6, or the gripping features 21 may be located completely below the anterior surface of the ring in the recess of the anterior opening 32A, as shown in FIG. 7. In FIG. 7, the haptic tips 16T and gripping features 21 are located completely within the recess and completely behind the anterior surface (i.e., they do not protrude forward of the anterior surface of the ring (the bottom of the recess is not considered part of the anterior surface of the ring)). The haptics may be in the form of a loop 16L. As shown in FIG. 7, the central opening may include a lens component 33 to form a lens for implantation in the ciliary sulcus, such as an implantable collamer lens (ICL), or an IOL for implantation in the subject's capsular bag.

[0066] 8 illustrates features of an embodiment of a drug delivery platform with haptic tips embedded in an IOL, including a lens 34 and an optional minimal ring 15 used to support the IOL lens. In this illustration, the haptic distal ends 16d and haptic tips 16T of the haptics 16, as well as those located at the haptic base 16B, can be positioned in through-holes 36 that communicate radially inward of the rear opening from the posterior surface of the lens near the periphery of the lens or frame or the periphery of the lens to an opening and recess 37 in the anterior surface 38 of the lens, with the haptic tips positioned entirely within the recess 37 and entirely behind the anterior surface (i.e., not protruding forward of the anterior optical surface of the lens (the bottom of the recess is not considered part of the anterior optical surface of the lens)), so that the haptic tips do not contact the iris but are still accessible for grasping with a hook or grasping forceps and can still slide within the through-hole to relieve compressive forces applied to the haptics by surrounding tissue. Figure 9 is a side view of a drug delivery platform or ciliary sulcus IOL showing a through hole terminating in an opening in the anterior surface of the ring or lens as described with respect to Figures 6, 7, and 8. Like the device of Figure 8, this device comprises an IOL that can be implanted in the ciliary sulcus or capsular bag of a subject.

[0067] FIG. 10 shows a variation that can be applied to the devices of FIGS. 2-9 above. Two different configurations of through-holes are shown in FIG. 10. Each end 41, 42 of haptic 43 and each end 44, 45 of haptic 46 are slidably disposed within chord-oriented holes 47, 48, 49, 50 (i.e., along the secant of the inner or outer circle of the ring) that communicate with or lead toward the inner surface of the ring from an opening 51 in the outer periphery of the ring. For haptic 43 (the upper haptic in the illustration), holes 52, 53 are blind holes that communicate with elongated cavities 54, 55 in the body of the ring between the front and rear surfaces of the ring, without communicating with either the front or rear surface of the ring or terminating in a recess in the rear surface of the ring as in FIG. 7. The elongated cavities are sized and dimensioned to allow translation of the haptic distal tip 16T within the elongated cavities, while each distal tip and access port is configured to prevent withdrawal of the tip from the cavity. For haptic 46 (the lower haptic in the illustration), holes 49, 50 are through-holes that communicate with openings 56, 57 in the inner wall of the ring, with the lumen of each hole preferably (in this embodiment) located between the anterior and posterior surfaces of the ring without communicating with either the anterior or posterior surfaces of the ring.

[0068] In this configuration, the ends 44, 45 of the haptics can be pushed inward by the surrounding tissue, making the haptics less likely to damage the surrounding tissue in the ciliary sulcus, as in the previous figure. Also, the chordally oriented holes through which the tips translate provide a longer travel for the distal tips. For the configuration in which the distal tips extend into the central opening, the travel of the distal tips remains near the inner wall of the ring and does not protrude as far into the central opening (compared to the radially oriented through-holes of FIG. 3).

[0069] Figure 10 also shows a form of drug delivery structure 58 that extends around the entire periphery of the posterior surface of ring 15, which may also be applied to the devices shown in Figures 3-9, 11-14, and 21-27. In other embodiments, drug delivery structure 58 extends around the entire periphery of the anterior surface of ring 15, which may also be applied to the devices shown in Figures 3-9, 11-14, and 21-27.

[0070] Each of the above-described devices can benefit from capturing the haptic distal end within the through-hole, with or without the benefit of exposed gripping features to facilitate implant removal. Haptic distal tip 16T, having a larger cross-section than the remainder of haptic end 16d, 41, 42, 44, 45, can function as a locking means to inhibit or prevent the second haptic end from being fully withdrawn during implantation. Holes 18, 49, 50, 52, 53 have lumens with smaller cross-sections than haptic distal tip 16T, allowing the distal tip and distal end to slide inward or flare outward to accommodate forces applied by the ciliary sulcus tissue, yet remain constrained within the hole so they cannot escape.

[0071] Further provided herein is an intraocular implant that can include one or more aqueous humor flow holes as described herein. In some embodiments, such a device is a ciliary sulcus implant. FIGS. 11 and 12 are anterior views of a ciliary sulcus implant / drug delivery platform. The implant can include one or more aqueous humor flow holes 18 and can be configured for use in the ciliary sulcus of the eye. The ciliary sulcus implant / drug delivery platform includes a ring 15, preferably flat like a washer, having planar anterior and posterior surfaces 15A and 15P and a central opening 17. The drug delivery structure is shown disposed within the ring 27. Haptics of any suitable configuration can be secured to the outer periphery of the drug delivery platform. The ring 15 comprises several aqueous humor through-holes 18 that communicate from openings 19 adjacent to or in the outer periphery or wall of the ring to openings 20 adjacent to the inner surface or wall of the ring and adjacent to the inner wall of the ring or adjacent to the anterior surface of the ring near the inner peripheral edge if the inner peripheral zone of the anterior surface is not occluded by the iris after placement. If the implant comprises a ciliary sulcus lens or ICL, the inner openings 20 may also open to the anterior surface of the lens in the peripheral region of the lens (outside the line of sight). The ring may have a rectangular radial cross-section (square or rectangular toroid) with a flat outer wall, a flat inner wall, and flat anterior and posterior surfaces, but one or more surfaces may be rounded, or the ring may have a circular or elliptical cross-section (torus).

[0072] Figure 12 is a front perspective view of the drug delivery platform of Figure 11, showing the through-holes 18 between the exterior and interior sides. While the through-holes are shown as radially oriented, they need not be strictly radial, as long as they communicate from the ciliary sulcus to the iris opening, allowing the flow of aqueous humor from the ciliary sulcus and into the anterior chamber. The through-holes may be chordally aligned along the secant line of the ring, and the through-holes need not be linear but may provide any type of fluid passageway communicating from the exterior of the ring and the ciliary sulcus (when implanted) to the interior of the ring and the pupil (when implanted). The fluid passageway may comprise a reticulated open-cell foam configured to form a network of connected open pores, in which case the ring may be partially or entirely composed of reticulated open-cell foam. The fluid passageway may also be provided by a wicking material, such as a wicking silicone, mesh or fibrous material, or a hydrophilic polymer (hydrogel), that constitutes all or part of the ring.

[0073] For implants intended as drug delivery platforms, drug delivery structures 27 may be located on the posterior surface of the ring, as shown in Figures 12 and 13. The rings shown in Figure 12 may alternatively be described, with reference to Figure 13, as a posterior ring 15P and an anterior ring 15A connected by a plurality of web members or walls 60. The plurality of web members or walls 60 separate a plurality of channels 61, which are surrounded by webbing on either side of the channels and anterior and posterior rings on the anterior and posterior boundaries of the channels.

[0074] FIG. 14 shows a ciliary sulcus lens 62 modified with aqueous humor through-holes 18 leading from the outer periphery or wall of the lens. The through-holes communicate from an opening 19 at the outer edge or periphery of the lens to an anterior opening 20 on the anterior surface of the lens itself. The anterior opening 20 is preferably located on the inner surface region 63 of the anterior surface that is not covered by the iris as it expands and contracts after implantation, as opposed to the outer region 64 of the anterior surface that is expected to be covered by the iris, but which preferably lies well outside the optical axis and field of view 65 perceivable by the subject. As with the previous figures, the fluid passageway may comprise through-holes as shown, or may comprise a reticulated open-cell foam, wicking material, mesh or fibrous material, or hydrophilic polymer (hydrogel) that constitutes all or part of the inner surface region 63.

[0075] The aqueous humor flow features described with respect to Figures 11-14 may be incorporated into other ocular implants, which may include a simple ring or scaffold for supporting a drug depot, an artificial iris, a ring with occluder paddles, an intraocular pressure sensor ring, an optical mask, etc., or an IOL configured for implantation in the posterior chamber and ciliary sulcus or capsular bag, as shown by Figure 14.

[0076] The use of through-holes with exits on the anterior surface of the lens can be applied to other ciliary sulcus implants where the central region of the implant is occupied by a device such as an occluder or optical mask.

[0077] The drug delivery structures may be positioned as shown in Figure 11, but may also be positioned around the ring, for example, radially aligned or adjacent to the haptic base and haptic openings, or may be positioned around the entire periphery of the posterior surface of the ring. The drug delivery structures may also function as structural elements that increase the stability / rigidity of the very thin silicone and may be positioned to enhance the ability of the silicone ring to maintain its circular shape (i.e., minimize deformation from its unconstrained circular form and avoid or minimize "ovalization" after implantation).

[0078] FIG. 15 is a front view of a ciliary sulcus implant / drug delivery platform such as that generally illustrated in FIG. 2. The ciliary sulcus implant and / or drug delivery platform of such an embodiment can include at least one, and preferably two or more, drug delivery structures 70, which are preferably arcuate with a planar anterior surface 70A and a posterior surface (not shown in FIG. 15). The drug delivery structures 70 are connected by a biasing member 71, leaving a central opening 17 defined by the inner surfaces of the drug delivery structures and the biasing member. The outer contour 70C of the drug delivery structure is preferably arcuate, more preferably circular, and sized to match the inner curvature / circumference of the ciliary sulcus of the eye where it is positioned when the outer contour 70C is biased against the inner peripheral region of the ciliary sulcus, such as the ciliary body and ciliary processes. The biasing member is configured to fit below the iris outside the optical field.

[0079] Figure 16 shows the drug delivery platform of Figure 15 in a compressed configuration. The device can be compressed toward the compressed, small diameter configuration shown in Figure 16, or can expand toward the open, larger, unconstrained, large diameter configuration of Figure 15. The device is compressed and folded into an injector for delivery into the eye, released into the eye, and allowed to elastically expand until its outer contour contacts the ciliary sulcus, or (depending on the initial state of the device) can be compressed to fit the drug delivery structure 70 within the ciliary sulcus.

[0080] The biasing members can be provided in a variety of forms. In one example, as shown in Figures 15 and 16, each biasing member comprises a separate compression spring connecting the two drug delivery structures shown. FIG. 17 shows a drug delivery platform 72 in which a biasing member is integrally formed with the drug delivery structure. The biasing member in this device comprises an outwardly expanding region 73 of the device disposed between drug depot regions 74 (although the entire device may comprise a drug depot configured to elute or otherwise deliver a therapeutic agent). A central opening 17 is formed within the device. The expanding region is configured as a living hinge joint defined by a notch 75 and is resiliently biased to open the device to the large-diameter, unconstrained configuration shown in FIG. 17. In this configuration, the hinge joint resiliently opens to bias the drug depot regions away from each other, but is resiliently compressible to the closed, small-diameter, constrained configuration shown in FIG. 18. The device is compressed and folded into an injector for delivery into the eye, released into the eye, and either allowed to resiliently expand until its outer contour contacts the ciliary sulcus, or compressed (depending on the initial state of the device) to conform the drug depot regions 74 within the ciliary sulcus.

[0081] Figure 18 shows the drug delivery platform of Figure 17 in a compressed configuration. The device can be compressed toward the compressed, small diameter configuration shown in Figure 18, or can expand toward the open, larger, unconstrained, large diameter configuration of Figure 17. The device is compressed and folded into an injector for delivery into the eye, released into the eye, and allowed to elastically expand until its outer contour contacts the ciliary sulcus, or it can be compressed (e.g., depending on the initial state of the device) to fit the drug depot region 74 within the ciliary sulcus.

[0082] In some embodiments, the arcuate drug delivery structures 70 of Figures 15-18 are configured to engage the equator or outer margin of the ciliary sulcus, while the biasing members 71 are configured to bias the arcuate drug delivery structures 70 to maintain the ciliary sulcus implant / drug delivery platform centered relative to the optical axis 10 of the eye (as shown in Figure 2). The arcuate drug delivery structures 70 may be limited in circumferential extent so that they do not substantially block the flow of aqueous humor. The biasing members are preferably thin in the anterior-posterior direction so that they again do not substantially block the flow of aqueous humor, but still allow aqueous humor to pass from the ciliary sulcus through the biasing members and into the anterior chamber.

[0083] Although the devices of the present disclosure, such as those shown in Figures 15-18, can be symmetrical with two drug delivery structures or drug depot regions, the devices can also be configured with an asymmetric distribution of drug delivery structures or drug depot regions, and the devices can be configured with one or several drug delivery structures or drug depot regions.

[0084] Some embodiments provided herein (e.g., as shown in Figures 15-18) are drug delivery intraocular implants that include one or more outwardly biased drug depots. In some cases, such drug delivery intraocular implants are drug delivery ciliary sulcus implants for implantation in the ciliary sulcus or capsular bag of a subject's (e.g., human) eye.

[0085] 19 illustrates a drug delivery platform having only a single arcuate drug delivery structure 70 with an arcuate outer contour 70C, similar to the drug delivery structure of FIG. 15, for example. A biasing member 71 connected by an arcuate connector 76 (which itself may be elastic and function as part of the biasing member) is operable to elastically bias the single arcuate drug delivery structure 70 away from the arcuate connector 76. The arcuate drug delivery structure 70 combines with the biasing member 71 and arcuate connector 76 to form an inner opening 17. The device may also be implanted in the lens capsule, in which case the illustrated drug delivery platform is inserted into the lens capsule and allowed to elastically expand within the capsule until the drug delivery structure, and, if applicable, the biasing member 71 or arcuate connector 76, abut against the inside of the capsule.

[0086] 20 shows a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible wire frame 80, the single drug delivery device comprising panels 81, 82 connected by struts 83 with openings between the panels and struts within which portions of the compressible wire frame are disposed. The wire frame can comprise any suitable flexible material, such as, for example, a compressible polymer or a compressible metal.

[0087] 21 and 22 show a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible ring 84, with a drug delivery structure 27 secured to the ring. Similar to the device in the previous figures, the device is compressed and folded into an injector for delivery into the eye, released into the eye, and allowed to elastically expand until its outer contour contacts the ciliary sulcus, or (depending on the initial state of the device) may be compressed to fit the drug delivery structure 27 (e.g., a delivery depot) into the ciliary sulcus. The compressible ring 84 may be formed as a drug delivery depot, but in certain embodiments, its purpose is to bias the drug delivery structure 27 (e.g., a drug depot) outward. FIG. 22 shows compression of the device shown in FIG. 21, such that the device assumes an ovular configuration.

[0088] 23-26 illustrate additional configurations of the drug delivery platform, including a flexible configuration that allows optimal fit of the device within the ciliary sulcus or capsular bag while minimizing or eliminating undesirable interactions with other eye tissues. Individual features in FIGS. 23-25 ​​may also apply to any of FIGS. 3-22, 26, and 27. The drug delivery platform may include a ring (as shown in FIGS. 23-25) or partial ring (as shown in FIG. 26) 15, which may be flat like a washer, with a planar anterior surface 15A and a planar posterior surface (not shown in FIGS. 23-26) and a central opening 17. In other embodiments, the anterior surface 15A or posterior surface may not be planar and may include a rounded top or other suitable configuration. In FIG. 23, closed-loop haptics 16C are attached at haptic base 16B. In FIG. 26, two closed-loop haptics 16C are attached at haptic base 16B.

[0089] The closed-loop haptics 16C can have an hourglass shape (similar to the upper haptics in FIGS. 23, 24, and 25) or any other suitable shape that promotes stabilization of the drug delivery structure and protection from damage to ocular tissue when implanted in a subject's eye. The drug delivery device can have a single closed-loop haptic or multiple closed-loop haptics. In other embodiments, additional haptics can be attached to the ring. As shown in FIGS. 23 and 24, a second set of haptics (reference numerals 16A and 16U in FIGS. 23 and 24) can be attached to the ring 15 at haptic base 16B. These additional haptics can take a variety of forms, including a U-shaped form (similar to the lower haptics in FIG. 24), an A-shaped form (similar to the lower haptics in FIG. 23), or any other suitable form as shown in FIGS. 3-10. Each of the closed-loop haptic and other haptics 16A, 16U can be attached at haptic base 16B in any suitable manner, including mechanically fastening the haptic to the ring, overmolding the haptic with the ring, fusing the haptic to the ring, attaching the haptic to the ring by heat shrink attachment, attaching the haptic to the ring by adhesive, or by any other suitable attachment. Alternatively, closed-loop haptic 16C and / or other haptics 16A, 16U can also be flexibly connected to ring 15 according to any of the methods described with respect to FIGS.

[0090] As shown in FIG. 24, the haptics 16U can also pass through through holes or channels 84 in the ring 15 such that the haptics 16U extend into the central opening 17 of the device to form gripping features 85.

[0091] As shown in Figure 25, the drug delivery device can include extensions of the ring 15 to form one or more retention features 15D. The retention features can comprise the same or different material as the ring. The retention features 15D can be contiguous with the ring or attached to the ring in any suitable manner.

[0092] The partial ring 15 of Figure 26 is compressible under the application of force, and the results of such compression on the device are shown in phantom in Figure 26. As with other devices of the present disclosure, the devices of Figures 23-26 can include a drug delivery structure, which can be located on the anterior surface 15A, the posterior surface, incorporated into the ring, or located in a separate compartment within the device.

[0093] 27 comprises a flexible, compressible ring structure 86 that forms a central opening 17. The device also includes one or more drug delivery structures 27 (attached to the ring structure at ring structure base 87), loops 71a that facilitate stabilization of the ring structure, and biasing members 71 disposed between the drug delivery structures 27. The ring structure may be constructed of the same materials as found in any of the haptics described in this disclosure.

[0094] In various embodiments of the present disclosure, haptics 16L, 16, 16C, 16A, 16U are connected to rings or partial rings 15, 83, 86 by mechanically fastening the haptics to the rings or partial rings, overmolding the haptics with the rings or partial rings, fusing the haptics to the rings or partial rings, attaching the haptics to the rings or partial rings with heat shrink attachment, attaching the haptics to the rings or partial rings with an adhesive, or any other suitable attachment. Such attachments include those shown in Figures 3-9 and 23-26.

[0095] Suitable materials for the haptics 16L, 16, 16C, 16A, 16U, 43, 46 of the present disclosure include biocompatible materials including polymeric materials such as polymethylmethacrylate (PMMA), polyvinylidene fluoride (PVDF), polypropylene (PP), and polyethersulfone (PES), or any combination thereof. Suitable materials for the rings or partial rings 15, 83, 86 of the present disclosure include biocompatible materials including polymeric materials such as silicone, acrylic, hydroxyethyl methacrylate (HEMA), polyethyl methacrylate (PEMA), polyethyl acrylate (PEA), and combinations thereof.

[0096] In various embodiments, the ocular implant of the present disclosure includes a ring or partial ring 15 comprising a first material and configured for implantation in a subject's eye, the ring or partial ring 15 characterized by an outer circumferential surface, an inner wall, and a central opening 17, and closed-loop haptics 16, 16C, 16L, 43, 46 comprising a second material and attached to the ring or partial ring at first haptic ends 16d, 41, 45 and second haptic ends 16d, 42, 44. The first and second materials have different chemical compositions, and the ring or partial ring is stiffer than the closed-loop haptics.

[0097] In various embodiments, the force applied to the ocular implants of the present disclosure (e.g., those shown in Figures 3-10 and 23-26) is sufficient to deform the haptics (e.g., closed-loop haptics 16, 16C, 16L, 43, 46) but not the ring or partial ring. Generally, under conditions present in the eye after implantation, the ring or partial ring retains its shape and the closed-loop haptics deform. In some embodiments, an applied force of 100 mN causes the ring or partial ring to retain its shape and the closed-loop haptics to deform. In other embodiments, an applied force of 80 mN causes the ring or partial ring to retain its shape and the closed-loop haptics to deform. In further embodiments, an applied force of 60 mN causes the ring or partial ring to retain its shape and the closed-loop haptics to deform. In other embodiments, an applied force of 50 mN causes the ring or partial ring to retain its shape and the closed-loop haptics to deform. In some embodiments, at an applied force of 40 mN, the ring or partial ring maintains its shape and the closed-loop haptics deform. In further embodiments, at an applied force of 30 mN, the ring or partial ring maintains its shape and the closed-loop haptics deform. In other embodiments, at an applied force of 20 mN, the ring or partial ring maintains its shape and the closed-loop haptics deform. In other embodiments, at an applied force of 10 mN, the ring or partial ring maintains its shape and the closed-loop haptics deform. In some embodiments, at an applied force of 5 mN, the ring or partial ring maintains its shape and the closed-loop haptics deform.

[0098] The drug delivery devices according to Figures 3-27 can be configured in a variety of ways to facilitate delivery of therapeutic agents to ocular tissues. Generally, as further described herein, one or more drug delivery structures 27, 58, 70, 81 may be provided as a drug depot or drug mass in the form of a block, slab, wafer, or the like containing a therapeutic agent or a therapeutic agent disposed in a matrix, or may contain an erodible therapeutic agent or a therapeutic agent in a matrix forming a drug-eluting structure. Each of the devices described herein for implantation in the posterior chamber and ciliary sulcus is also suitable for implantation in the capsular bag. The devices of the present disclosure are configured to deliver a therapeutic agent to the capsular bag at the equator of the capsular bag or to the posterior chamber and ciliary sulcus. For example, the therapeutic agent may function to inhibit lens endothelial cell proliferation and activity and the development of posterior capsular opacification (e.g., cytoskeletal drugs, latrunculin, anti-VEGF, etc.).

[0099] For each of the devices described herein and shown in Figures 3-27, drug delivery structures 27, 58, 70, 81 may be disposed on or in the rear surface 15P, on or in the front surface 15A, or a combination thereof. The drug delivery structures may be affixed directly to the rear and / or front surface, disposed in compartments affixed to the rear surface, or otherwise incorporated into the device. The ring or partial ring 15, 83, 86 may itself include drug delivery structures 27, 58, 70, 81, for example, comprised of a therapeutic agent in a silicone matrix.

[0100] II. Methods of Implanting and Operating Ocular Implants The presently disclosed intraocular implants, such as those shown in Figures 3-27, can be used in a variety of applications in a subject's eye. In some embodiments, the drug delivery platform of such devices described herein can be used in methods of intraocularly delivering a therapeutic agent to a subject's eye, to the ciliary sulcus. In various aspects, the presently disclosed drug delivery devices include closed-loop haptics, or more specifically, U-loop haptics. Using various embodiments of the present disclosure, a surgeon can insert the presently disclosed drug delivery device into a subject's eye, positioning the haptics under the iris and centering the ring relative to the capsular bag and lens.

[0101] In some aspects, the devices of the present disclosure comprise an IOL. For example, such devices comprising an IOL are shown as an IOL disposed within central opening 17 of the present disclosure and surrounded by optional ring 15, including for the devices shown in Figures 7 and 8, or as shown in Figures 3-6, 10-14, and 23-25. In various embodiments, the devices of the present disclosure can be implanted in a subject's eye in which an IOL device has previously been implanted (e.g., as a capsular bag device), or in a subject's eye that still contains a natural lens and has an intact capsular bag.

[0102] The devices of the present disclosure, such as those shown in Figures 3-27, may be implanted so that the device is either centered or not centered on the optical axis of the eye. Then, either during surgery or much later after implantation, the surgeon can remove the drug delivery platform by inserting a tip-grasping instrument into the eye through the incision (at the base of the cornea, at the "clear cornea" or "limbic entry point" along the limbus, or even at the "scleral entry point"), such as a Sinskey hook or micro-grasping forceps, under the cornea from a point opposite the tip to be grasped or from an entry point circumferentially displaced (around the edge of the cornea) from the tip to be grasped, whereby the instrument pulls the tip radially inward, then grasps the tip and gently pulls it radially inward across the opening to disengage the haptic from the ciliary sulcus and move it to a position anterior to the iris, and repeating this process from the other side of the cornea (the other side of the limbus (the boundary between the cornea and sclera) or the other side of the anterior chamber) to release a second haptic tip and remove the drug delivery platform through the incision under the cornea. This removal procedure can be performed without inserting an instrument into the ciliary sulcus, grasping and directly manipulating the loop portion of the haptic, exposing the iris to the haptic tip, or exposing the haptic tip within the ciliary sulcus.

[0103] Although described with respect to drug delivery platforms, the modified haptic structures described above and illustrated in Figures 3-10 and 23-26 can be incorporated into other ocular implants, which may include simple rings or scaffolds for supporting drug depots, artificial irises, rings with occluder paddles, intraocular pressure sensor rings, optical masks, etc., or IOLs configured for implantation in the posterior chamber and ciliary sulcus as illustrated by Figures 7 and 8. Additionally, the devices described for implantation in the posterior chamber and ciliary sulcus can also be implanted in the lens capsule to take advantage of trapped haptics, or aspects of stress relief by trapping the haptics in holes, or the advantage of grasping the haptic tips for adjustment and removal, in combination or alone.

[0104] In various embodiments of the present disclosure, the haptic tip 16T may preferably be configured to facilitate engagement with a Thinsky hook, micrograsping forceps, or other instrument. In addition to haptic tips 16T incorporating gripping features 21, additional devices of the present disclosure incorporate gripping features 85. As shown in FIGS. 3, 5, 6, 10, and 24, the haptic tip 16T may be configured with gripping features 21, 85 such as eyelets, or other configurations may be used, such as pinholes (sized to accept a Thinsky hook), optional serrations, flanges, barbs, wrench flats, or other flat surfaces that can be grasped by micrograsping forceps. For the devices shown in FIGS. 3-10, if other suitable gripping instruments are available or if manipulation as described below is not anticipated, the tip may terminate bluntly without a gripping feature. Without requiring insertion of an instrument into the ciliary sulcus or posterior chamber, the haptics can be removed from the ciliary sulcus position without engaging the iris or surrounding tissue and elevated above the resting plane for easier removal, thus minimizing trauma to associated tissue. These haptics 16L, 16, 16C, 16A, 16U, 43, 46 (including the haptic loops 16L, 16, 16C, 43, 46) can also aid in device placement during initial implantation, allowing the haptics to be pulled together (toward the geometric center of the entire device) and then released (allowing them to open into the ciliary sulcus) when the ring is properly positioned. In various aspects, the constrained nature of the haptics (the closed-loop haptics of the present disclosure) may also make folding the device for insertion into the eye easier and more reproducible. This is because the haptics are constrained in a known space and axis, making it easier to compress the device into the injector and then inject or place it into the eye.

[0105] III. METHODS OF TREATING SUBJECTS USING OCULAR IMPLANTS The drug delivery devices of the present disclosure, such as those shown in Figures 3-27, can be used in methods for intraocular delivery of a therapeutic agent to a subject's eye, including the subject's ciliary sulcus or lens capsule. For example, for the treatment of glaucoma, the therapeutic agent in the drug delivery structures 27, 58, 81 can be a therapeutic agent effective in reducing intraocular pressure, such as bimatoprost. In some embodiments, a surgeon inserts any of the devices of the present disclosure (e.g., as shown in Figures 3-27) into the posterior chamber, located between the iris and the lens capsule, with the anterior surface facing the iris and the posterior surface facing the lens capsule, with any haptics used extending into the ciliary sulcus.

[0106] For each of the embodiments described herein, including those shown in Figures 3-27, the drug delivery device can be configured to deliver various therapeutic agents to treat a condition or disease in a subject in need of treatment. Treatment includes any amelioration of the condition or disease, or any improvement (subjective or objective) of any of their symptoms. The devices of the present disclosure can be used to treat age-related macular degeneration, amblyopia, cataracts, color blindness, diabetic retinopathy, dry eye, floaters, glaucoma, conjunctivitis, refractive errors, retinal detachment, and any combination thereof. In some embodiments, the therapeutic agents can include bimatoprost, brimonidine, latanoprost, timolol, pilocarpine, brinzolamide, and other drugs in the general categories of beta-blockers, alpha-agonists, Rho-kinase (ROCK) inhibitors, adenosine receptor agonists, carbonic anhydrase inhibitors, adrenergic and cholinergic receptor activators, and prostaglandin analogs, which can be incorporated into the drug delivery device to treat glaucoma. Aflibercept, bevacizumab, pegaptanib, ranibizumab, steroids, and aptamers may be incorporated into drug delivery devices to treat wet macular degeneration. Complement factors, antioxidants, and anti-inflammatory drugs may be incorporated into drug delivery devices to treat dry macular degeneration. Methotrexate, antibodies, dexamethasone, triamcinolone, and other steroid drugs may be incorporated into drug delivery devices to treat uveitis. Antiproliferative drugs, antimitotic drugs, anti-inflammatory drugs, and other drugs that inhibit lens epithelial cell proliferation may be incorporated into drug delivery devices to treat posterior capsule opacification. Antibiotics such as fluoroquinolones, nonsteroidal drugs such as ketorolac, and steroids such as prednisolones may be incorporated into drug delivery devices to treat infection and inflammation for postoperative management after cataract surgery.

[0107] Further provided herein are methods of treating a subject using a drug delivery ocular implant comprising an outwardly biased drug depot, for example, as shown in Figures 21, 22, and 27. Additional embodiments of the present disclosure (e.g., any of Figures 3-20 and 23-26) can be modified to comprise one or more outwardly biased drug depots. As disclosed herein, such drug delivery ocular implants are drug delivery ciliary sulcus implants for implantation in the ciliary sulcus or capsular bag of a subject's eye. In various embodiments, in use, ciliary sulcus implants and / or drug delivery platforms such as those shown in Figures 21, 22, and 27 herein (or other embodiments modified to incorporate a drug depot) comprising such outwardly biased drug depots can be used in methods of intraocularly delivering a therapeutic agent to a subject's eye by inserting the drug delivery structure into the ciliary sulcus, inserting the device into the anterior chamber, and elastically expanding the device. Upon release into the anterior chamber, the biasing members elastically expand circumferentially, pushing the drug delivery structures outward within the ciliary sulcus until they abut against anatomical structures at the sulcus angle.

[0108] Provided herein are methods of using an intraocular implant including one or more aqueous humor flow holes (e.g., as shown in FIGS. 11-14 or as incorporated in any of FIGS. 3-10 and 15-17). In various cases, such implants are ciliary sulcus implants for implantation in the ciliary sulcus or capsular bag of a subject's eye. After implantation, the fluid passages allow aqueous humor to pass through the ring and prevent fluid from accumulating in the ciliary sulcus and posterior chamber. When implanted in the capsular bag such that the passages allow fluid flow from the inner wall of the ring to openings 19 adjacent the periphery of the ring, therapeutic agents can be delivered from the central opening to the equator of the capsular bag.

[0109] While preferred embodiments of the devices and methods are described in relation to the environment in which they were developed, these embodiments are merely illustrative of the principles of the invention. Elements of various embodiments may be incorporated into each of the other varieties to obtain the benefits of these elements in combination with such other varieties, and various beneficial features may be utilized in the embodiments alone or in combination with each other. Other embodiments and configurations may be devised without departing from the spirit of the invention and the scope of the appended claims.

Claims

1. 1. An ocular implant configured for implantation into an eye of a subject, comprising: The ocular implant comprises: a ring (15) configured for implantation in the eye of the subject, the ring (15) having an outer circumferential surface, an inner wall, and a central opening (17); haptics (16, 16L, 43, 46) connected to the ring at first haptic ends (16d, 41, 45) and second haptic ends (16d, 42, 44); The ring has holes (18, 49, 50) that lead from the openings (19, 51) in the outer circumferential surface toward the inner wall, An ocular implant, wherein the second haptic end (16d, 42, 44) is positioned within the hole (18, 48, 50, 52) and is slidably positioned within the hole, such that the haptics are deformable by forces applied by tissue into which the ocular implant is implanted and which may act to push the second haptic end into the hole (18, 48, 50, 52).

2. 2. The ocular implant of claim 1, wherein the second haptic end (16d, 42, 44) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44).

3. 3. The ocular implant of claim 1 or 2, further comprising a lens (34) disposed within the central opening (17).

4. 4. An ocular implant as described in any one of claims 1 to 3, wherein the second haptic end (16d, 42, 44) has a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44), and the hole (18, 36, 48, 50) has an inner cavity with a smaller cross-section than the haptic distal tip (16T), thereby preventing or restricting the second haptic end from slipping out of the hole.

5. 5. The ocular implant of claim 1, further comprising a gripping feature (21) disposed on the second haptic end (16d, 42, 44), the gripping feature configured for engagement of a gripping instrument.

6. An ocular implant as described in any one of claims 1 to 5, wherein the hole (18, 50) leading from the opening (19, 51) in the outer peripheral surface toward the inner wall is a through hole communicating with an opening (20, 56) in the inner wall of the ring, and the second haptic end (16d, 42, 44) has a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44), and the haptic distal tip (16T) is positioned in the central opening (17).

7. 7. An ocular implant as described in any one of claims 1 to 6, wherein the first haptic end (16d, 41, 45) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the first haptic end (16d, 41, 45).

8. 8. An ocular implant as described in any one of claims 1 to 7, wherein the first haptic end (16d, 41, 45) has a haptic distal tip (16T) having a larger cross-section than the remainder of the first haptic end, and the hole (18, 47, 49) has an inner cavity with a smaller cross-section than the haptic distal tip (16T), thereby preventing or restricting the first haptic end from slipping out of the hole.

9. An ocular implant as described in any one of claims 1 to 8, wherein the hole (18, 50) is a first hole, the ring (15) further comprises a second hole leading from a second opening in the outer peripheral surface toward the inner wall, and the first haptic end (16d, 41, 45) is positioned within the second hole and is slidably positioned within the hole, whereby the haptic is deformable by a force applied by tissue into which the ocular implant is embedded, pushing the first haptic end (16d, 41, 45) into the second hole.

10. An ocular implant as described in any one of claims 1 to 9, wherein the haptics (16, 16L, 43, 46) form a closed loop between the first haptic end (16d, 41, 45) and the second haptic end (16d, 42, 44).

11. An ocular implant as described in any one of claims 1 to 10, further comprising a drug delivery structure (27, 81, 82) configured to be coupled to the ring (15).

12. The ocular implant of claim 11 , wherein the drug delivery structure (27, 81, 82) contains a therapeutic agent.

13. The ocular implant of claim 12, wherein the therapeutic agent is disposed in a polymer matrix.

14. The therapeutic agent comprises one or more of a prostaglandin analogue, an alpha agonist, a Rho-kinase (ROCK) inhibitor, an adenosine receptor agonist, a carbonic anhydrase inhibitor, an adrenergic and / or cholinergic receptor activator, a steroid, an aptamer, a complement factor, an antioxidant, an anti-inflammatory agent, an antibody, an anti-proliferative agent, an anti-mitotic agent, or an anti-inflammatory agent; The ocular implant of claim 12 or 13, wherein the therapeutic agent comprises bimatoprost.

15. An ocular implant as described in any one of claims 11 to 14, wherein the drug delivery structure (27, 81, 82) is bonded to a rear surface of the ring (15), or the drug delivery structure (27, 81, 82) comprises a pair of arcuate structures bonded to the ring (15).